Ultra-processed foods: time to put health before profit The Lancet + + +...

Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02155-5/abstract?dgcid=raven_jbs_etoc_feature_lancet Ultra-processed foods: time to put health before profit The Lancet https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02322-0/fulltext?dgcid=raven_jbs_etoc_feature_lancet Dec 06, 2025 Volume 406Number 10520p2601-2726 https://www.thelancet.com/journals/lancet/issue/vol406no10520/PIIS0140-6736(25)X0049-0